HORSHAM, Pa., Sept. 27, 2018 /PRNewswire/ -- Janssen Biotech, Inc. (Janssen) announced today its decision not to continuethe collaboration and license agreement with Geron Corporation for imetelstat. The decision not to continue the collaboration is the result of a strategic portfolio evaluation and prioritization of assets within the robust Janssen portfolio. Janssen
The imetelstat collaboration began on November 13, 2014 when Janssen entered into an exclusive worldwide collaboration and license agreement with Geron to develop and commercialize imetelstat in oncology, including hematologic myeloid malignancies.
About the Janssen Pharmaceutical Companies of Johnson & Johnson At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Biotech, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Media Inquiries: Brian Kenney Phone: 1-215-620-0111
Satu Kaarina Glawe Phone: +49 172 294 6264
Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955
Lesley Fishman Phone: 1-732-524-3922
U.S. Medical Inquiries: 1-800-526-7736
View original content:http://www.prnewswire.com/news-releases/janssen-elects-not-to-continue-agreement-with-geron-for-imetelstat-300720121.html
SOURCE Janssen Biotech, Inc.
Subscribe to our Free Newsletters!